Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa, PS0017 Study Group, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa, PS0017 Study Group
Abstract
Introduction: Certolizumab pegol (CZP), the Fc-free, PEGylated anti-tumor necrosis factor, is approved for the treatment of moderate to severe plaque psoriasis (PSO) in Western countries and in Japan, among other indications.
Methods: We report results from the first 16 weeks of a 52-week phase 2/3 trial of CZP in Japanese patients with PSO. Patients ≥ 20 years with PSO ≥ 6 months (Psoriasis Area and Severity Index [PASI] ≥ 12, body surface area affected ≥ 10%, and Physician's Global Assessment [PGA] ≥ 3 on a 5-point scale) were randomized 2:2:1 to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (400 mg weeks 0/2/4), or placebo Q2W. Outcomes assessed to week 16: PASI 75, PASI 90, PGA 0/1 (Markov chain Monte Carlo), Dermatology Life Quality Index (DLQI 0/1) and Itch Numeric Rating Scale (INRS 0) (non-responder imputation), and DLQI and INRS change from baseline (last observation carried forward). Safety data were reported for patients receiving ≥ 1 dose of study medication through weeks 0-16; adverse events were evaluated using Medical Dictionary for Regulatory Activities version 18.1.
Results: A total of 127 patients were randomized to CZP 400 mg Q2W (N = 53), CZP 200 mg Q2W (N = 48), placebo (N = 26). Week 16 responder rates for CZP 400 mg/200 mg Q2W versus placebo were 87.1%/73.0% versus 7.9% for PASI 75; 75.7%/53.8% versus 0.2% for PASI 90; 66.7%/52.7% versus 0.0% for PGA 0/1 (all p < 0.0001 for both CZP doses versus placebo). Significant improvements in DLQI and INRS were reported at week 16 by patients receiving both CZP doses compared with placebo (p < 0.0001). Incidence of treatment-emergent adverse events within the CZP 400 mg Q2W, CZP 200 mg Q2W, and placebo groups were 326.1, 404.9, and 682.4 per 100 patient-years. No new safety signals were identified compared to previously reported data.
Conclusion: CZP dosed at 400 mg or 200 mg Q2W was associated with improved PSO signs and symptoms.
Trial registration: ClinicalTrials.gov identifier, NCT03051217.
Keywords: Certolizumab pegol; Japan; Plaque psoriasis; Tumor necrosis factor-alpha.
Figures
References
- Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450. doi: 10.1136/bmjopen-2014-006450.
- Napolitano M, Caso F, Scarpa R, et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–1901. doi: 10.1007/s10067-016-3295-9.
- National Psoriasis Foundation: Plaque Psoriasis. 2019. . Accessed 4 Sept 2019.
- Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343–350. doi: 10.1016/j.clindermatol.2013.11.001.
- Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41–55. doi: 10.1016/j.det.2014.09.004.
- Ito T, Takahashi H, Kawada A, Iizuka H, Nakagawa H, Research JSFP Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol. 2018;45(3):293–301. doi: 10.1111/1346-8138.14105.
- Belinchón I, Vanaclocha F, De La Cueva-Dobao P, et al. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. J Dermatol Treat. 2015;26(4):318–325. doi: 10.3109/09546634.2014.983039.
- Honma M, Shibuya T, Iwasaki T, et al. Prevalence of coronary artery calcification in Japanese patients with psoriasis: a close correlation with bilateral diagonal earlobe creases. J Dermatol. 2017;44(10):1122–1128. doi: 10.1111/1346-8138.13895.
- Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Erratum to “Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis”[J Dermatol Sci 2009; 54: 61–3] J Dermatol Sci. 2009;55(1):74–76. doi: 10.1016/j.jdermsci.2009.04.003.
- Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizuka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci. 2010;57(2):143–144. doi: 10.1016/j.jdermsci.2009.11.002.
- Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi: 10.1371/journal.pmed.1002739.
- Borska L, Kremlacek J, Andrys C, et al. Systemic inflammation, oxidative damage to nucleic acids, and metabolic syndrome in the pathogenesis of psoriasis. Int J Mol Sci. 2017;18(11):2238. doi: 10.3390/ijms18112238.
- Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol. 2010;24(9):989–1004.
- Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012;37(3):84–88.
- Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version) J Dermatol. 2013;40(9):683–695. doi: 10.1111/1346-8138.12239.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. doi: 10.1016/j.jaad.2008.02.039.
- National Institute for Health and Care Excellence. Psoriasis Management. 2019. . Accessed 19 Mar 2019.
- Silfvast-Kaiser A, Paek SY, Menter A. Anti-IL17 therapies for psoriasis. Expert Opin Biol Th. 2019;19(1):45–54. doi: 10.1080/14712598.2019.1555235.
- Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi: 10.1016/j.jaad.2020.02.044.
- Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi: 10.1136/annrheumdis-2017-212196.
- Weir N, Athwal D, Brown D, et al. A new generation of high-affinity humanized PEGylated Fab′ fragment anti-tumor necrosis factor-α monoclonal antibodies. Therapy. 2006;3(4):535–546.
- US Food and Drug Administration. Certolizumab Pegol Prescribing Information. 2019. . Accessed 15 Nov 2019.
- European Medicines Agency. Certolizumab Pegol Summary of Product Characteristics. . Accessed 15 Nov 2019.
- Certolizumab Pegol Product Information. . Accessed 15 Nov 2019.
- Pharmaceuticals and Medical Devices Agency. . Accessed 15 Nov 2019.
- Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT) J Am Acad Dermatol. 2018;79(2):266–76.e5. doi: 10.1016/j.jaad.2018.04.013.
- Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) J Am Acad Dermatol. 2018;79(2):302–14.e6. doi: 10.1016/j.jaad.2018.04.012.
- Blauvelt A, Reich K, Lebwohl M, et al. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol. 2018;79(2):266–276. doi: 10.1016/j.jaad.2018.04.013.
- Criteria Committee of the New York Heart Association . Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis. 6. Boston: Little, Brown and Co.; 1964.
- Kimball A, Naegeli A, Edson-Heredia E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Brit J Dermatol. 2016;175(1):157–162. doi: 10.1111/bjd.14464.
- Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Group AMS Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37(4):299–310. doi: 10.1111/j.1346-8138.2009.00748.x.
- Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Group JUS Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252. doi: 10.1111/j.1346-8138.2011.01347.x.
- Nakagawa H, Niiro H, Ootaki K, Group JBS Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52. doi: 10.1016/j.jdermsci.2015.10.009.
- Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron GS, Group JU-S Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1) J Dermatol. 2017;44(11):1285–1290. doi: 10.1111/1346-8138.13927.
- Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062. doi: 10.1111/1346-8138.14504.
- Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039–1046. doi: 10.1111/1346-8138.12668.
- Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–8130. doi: 10.1016/j.jaad.2013.12.018.
- Dattola A, Balato A, Megna M, et al. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. J Eur Acad Dermatol Venereol. 2020;34(12):2839–2845. doi: 10.1111/jdv.16606.
Source: PubMed